ClinicalTrials.gg
RecruitingNCT05052853Updated Mar 24, 2026

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

A Phase 2 interventional study of NMDAE and Placebo Cap in Prodromal Schizophrenia, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 13 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
13 Years to 45 Years
Sex
All
01

Study summary

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.

Read the detailed description

Several lines of evidence suggest that NMDA hypotheses have been implicated in schizophrenia. Previous studies found that some NMDA-enhancing agents were able to benefit the treatment of schizophrenia. Whether an NMDA-enhancer (NMDAE) can benefit the treatment of prodromal schizophrenia deserves study. Therefore, this study aims to compare NMDAE and placebo in the treatment of prodromal schizophrenia.

The subjects with prodromal schizophrenia at first receive 6 weeks of health-promotion intervention (including exercise and education). A total of 48 subjects who do not respond sufficiently to the health-promotion program are then recruited to this 12-week, randomized, double-blind, placebo-controlled trial, which aims to compare treatment response of NMDAE vs. placebo in 1:1 ratio. Clinical performances and side effects are measured at weeks -6 (before the screening phase), 0 (baseline of the drug trial), 2, 4, 6, 9, and 12. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests.

The efficacies of NMDAE and placebo will be compared. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

02

Conditions studied

  • Prodromal Schizophrenia

Keywords

  • Schizophrenia
  • Prodrome
  • NMDA
03

In context

Schizotypal Personality Disorder

49 studies on the registry are indexed under Schizotypal Personality Disorder; 12 are open to participants now.

This study's planned enrollment of 48 is below the median of 54 across 41 interventional studies indexed under Schizotypal Personality Disorder.

Browse Schizotypal Personality Disorder studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 480 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals meeting Criteria of Prodromal Syndrome (at least one of the following: 1. attenuated positive symptoms; 2. brief intermittent psychotic symptoms; 3. genetic risk and deterioration).
  • Subjects remain symptomatic (scoring at least 20 on the Scale of Prodromal Symptoms [SOPS] total score) after the 6-week screening phase (which contains the health-promotion program) and before the 12-week drug-trial period.
  • Subjects may be receiving ongoing treatment with antipsychotic medications, or may be medication-free for at least 12 weeks.For the subjects who have already been on such medications, the medications need to be continued for at least 4 weeks before the screening phase and the doses need to be kept unchanged during the study period. For those who have not yet been on such medications, these medications are forbidden during the study period.
  • Subjects agree to participate in the study and provide written after complete description of the study. For the subject \< 20 years old, a parent also has to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • diagnosis of intellectual disability, substance (including alcohol) use disorder, schizophrenia, schizophreniform disorder, delusional disorder, schizoaffective disorder, substance/medication-induced psychotic disorder, or psychotic disorder due to another medical condition.
  • History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study.
  • laboratory screening tests (including blood routine, biochemical tests)
  • Pregnancy or lactation
  • Inability to follow protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    NMDAE

    An NMDA enhancer

    Drug: NMDAE

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Cap

Interventions

  • DrugNMDAE

    Use of an NMDA enhancer for the treatment of prodromal schizophrenia .

  • DrugPlacebo Cap

    Use of placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change from baseline in Scale of Prodromal Symptoms [SOPS] total score

    Assessment of overall prodromal symptoms. Minimum value: 0, maximum value: 114, the higher scores mean a worse outcome. As shown in "Detailed Description", "mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). That is, GEE is used for analyzing the changes from baseline in repeated-measure assessments by a single analysis (but not multiple analyses).

    Time frame: week 0, 2, 4, 6, 9, 12

Secondary outcomes

  1. Change from baseline in SOPS Positive Symptom Scale score

    Assessment of positive prodromal symptoms. Minimum value: 0, maximum value: 30, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  2. Change from baseline in SOPS Negative Symptom Scale score

    Assessment of negative prodromal symptoms. Minimum value: 0, maximum value: 36, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  3. Change from baseline in SOPS Disorganization Symptom Scale score

    Assessment of disorganization prodromal symptoms. Minimum value: 0, maximum value: 24, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  4. Change from baseline in SOPS General Symptom Scale score

    Assessment of general prodromal symptoms. Minimum value: 0, maximum value: 24, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  5. Change from baseline in Scales for the Assessment of Negative Symptoms (SANS) total score

    Assessment of schizophrenia negative symptoms. Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  6. Change from baseline in Clinical Global Impression

    Assessment of general impression. Minimum value: 1, maximum value:7, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  7. Change from baseline in Global Assessment of Functioning

    Assessment of social, occupational, and psychological function. Minimum value: 1, maximum value:100, the higher scores mean better function.

    Time frame: week 0, 2, 4, 6, 9, 12

  8. Change from baseline in Hamilton Rating Scale for Depression

    Assessment of depressive symptoms. Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  9. Change from baseline in Quality of Life Scale

    Assessment of life quality. Minimum value: 0, maximum value:126, the higher scores mean a better outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  10. Change from baseline in Cognitive function

    The measure is the composite from multiple measures. All tests have no unit. For the domain (a. and c.) with more than one test, a composite T score will be calculated by standardizing the average of each T score. Furthermore, a global composite score (for all seven domains) and a neurocognitive composite score (for the first 6 domains, a-f) will be also calculated by standardizing the average of the T score of each domain (Lane HY et al, JAMA Psychiatry. 2013). Ten tests for assessment of 7 cognitive domains: 1. speed of processing (assessed by Category Fluency, Trail Marking A, WAIS-III Digit Symbol-Coding); 2. sustained attention (Continuous Performance Test); 3. working memory: verbal (digit span) and nonverbal (spatial span); 4. verbal learning and memory (WMS-III, word listing); 5. visual learning and memory (WMS-III, visual reproduction); 6. reasoning and problem solving (WISC-III, Maze); 7. social cognition (MSCEIT Version 2)

    Time frame: Week 0, 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Oct 2026, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 22, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05052853
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Nov 1, 2021
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Hsien-Yuan Lane, M.D., Ph.D
Contact
hylane@gmail.com
886 4 22052121 ext. 1855

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion